Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform recommendation.
Analyst Price Forecast Suggests 232.06% Upside
As of February 19, 2025, the average one-year price target for Altimmune is $22.15/share. The forecasts range from a low of $12.12 to a high of $29.40. The average price target represents an increase of 232.06% from its latest reported closing price of $6.67 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Altimmune is 6MM, an increase of 31,210.00%. The projected annual non-GAAP EPS is -2.13.
What is the Fund Sentiment?
There are 327 funds or institutions reporting positions in Altimmune. This is an increase of 6 owner(s) or 1.87% in the last quarter. Average portfolio weight of all funds dedicated to ALT is 0.05%, an increase of 19.06%. Total shares owned by institutions increased in the last three months by 1.94% to 46,222K shares. 
The put/call ratio of ALT is 0.28, indicating a bullish outlook.
What are Other Shareholders Doing?
Ameriprise Financial holds 5,255K shares representing 7.39% ownership of the company. In its prior filing, the firm reported owning 3,876K shares , representing an increase of 26.24%. The firm increased its portfolio allocation in ALT by 59.00% over the last quarter.
Tang Capital Management holds 2,750K shares representing 3.87% ownership of the company. No change in the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,584K shares representing 3.63% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 1,921K shares representing 2.70% ownership of the company. In its prior filing, the firm reported owning 1,851K shares , representing an increase of 3.66%. The firm increased its portfolio allocation in ALT by 17.44% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 1,797K shares representing 2.53% ownership of the company. In its prior filing, the firm reported owning 1,791K shares , representing an increase of 0.34%. The firm increased its portfolio allocation in ALT by 42.37% over the last quarter.
Altimmune Background Information
(This description is provided by the company.)
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
